Contribute Try STAT+ Today

Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH — a decision that has obvious negative consequences for Intercept but could also raise concerns for other drugmakers developing similar treatments.

According to a statement from Intercept, FDA officials determined the “predicted benefit” of the company’s drug called obeticholic acid, or OCA, “does not sufficiently outweigh the potential risks” to support approval as a treatment for patients with NASH. The FDA further recommended that Intercept submit additional efficacy and safety data from its Phase 3 clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The NASH companies that will benefit from this are the ones that have clinical outcomes for the endpoints. Not just some measure of histology under the microscope.

Comments are closed.